Biogen Inc.

XNASHealth care

Last traded price · USD

$249.38

+0.18%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 15:17 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $248.93
Volume: 2
Day's high: —
Day's low: —

In brief

Biogen Inc. is a health care company listed on Nasdaq, valued at about $36.86B.
Its shares closed at $248.93 on 3 Nov 2026, up 64.4% over the past year.
From India you can buy BIIB in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Biogen Inc. (BIIB) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole BIIB share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade BIIB options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +11.3% (SPY −2.6%, XLV +9.9%). 3 months: +19.4% (SPY −2.2%, XLV +13.5%). 1 year: +64.4% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: BIIB, SPY and XLV · as of 3 Nov 2026
3.8% below its 52-week high
Closed at $248.93 on 3 Nov 2026: 3.8% below the 52-week high of $258.78 (28 Oct 2026) and 67.6% above the low of $148.51 (5 Nov 2025).
Daily price bars, split-adjusted · as of 3 Nov 2026
Above its 50- and 200-day averages
The 3 Nov 2026 close of $248.93 was 9.0% above its 50-day average ($228.34) and 23.2% above its 200-day average ($202.00). It has closed above the 200-day for 296 sessions, since 2 Sep 2025. The 50-day average crossed above the 200-day on 25 Sep 2025, 278 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
Short interest at 3.7% of shares outstanding
5.5M shares were sold short at the 15 Oct 2026 settlement, 3.7% of the 147.8M shares outstanding; covering them would take 4.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month+11.3%

6 months+31.6%

1 year+64.4%

5 years−11.0%

Newswire

About

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Website

Notable moves

October 1, 2025
+10.09%
September 28, 2022
+39.85%
December 29, 2021
+9.46%

Newswire

About

Website

Notable moves

October 1, 2025
+10.09%
September 28, 2022
+39.85%
December 29, 2021
+9.46%

Biogen Inc.

XNASHealth care

Last traded price · USD

$249.38

+0.18%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 15:17 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $248.93
Volume: 2
Day's high: —
Day's low: —

In brief

Biogen Inc. is a health care company listed on Nasdaq, valued at about $36.86B.
Its shares closed at $248.93 on 3 Nov 2026, up 64.4% over the past year.
From India you can buy BIIB in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Biogen Inc. (BIIB) shares from India?

Do I need the price of a whole BIIB share to invest?

How much can I invest in US stocks in a year?

Can I trade BIIB options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +11.3% (SPY −2.6%, XLV +9.9%). 3 months: +19.4% (SPY −2.2%, XLV +13.5%). 1 year: +64.4% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: BIIB, SPY and XLV · as of 3 Nov 2026
3.8% below its 52-week high
Closed at $248.93 on 3 Nov 2026: 3.8% below the 52-week high of $258.78 (28 Oct 2026) and 67.6% above the low of $148.51 (5 Nov 2025).
Daily price bars, split-adjusted · as of 3 Nov 2026
Above its 50- and 200-day averages
The 3 Nov 2026 close of $248.93 was 9.0% above its 50-day average ($228.34) and 23.2% above its 200-day average ($202.00). It has closed above the 200-day for 296 sessions, since 2 Sep 2025. The 50-day average crossed above the 200-day on 25 Sep 2025, 278 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
Short interest at 3.7% of shares outstanding
5.5M shares were sold short at the 15 Oct 2026 settlement, 3.7% of the 147.8M shares outstanding; covering them would take 4.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month+11.3%

6 months+31.6%

1 year+64.4%

5 years−11.0%

Newswire

About

Website

Notable moves

October 1, 2025
+10.09%
September 28, 2022
+39.85%
December 29, 2021
+9.46%

Newswire

About

Website

Notable moves

October 1, 2025
+10.09%
September 28, 2022
+39.85%
December 29, 2021
+9.46%

Biogen Inc.

Biogen Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

3.8% below its 52-week high

Above its 50- and 200-day averages

Short interest at 3.7% of shares outstanding

Biogen Inc.

Biogen Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

3.8% below its 52-week high

Above its 50- and 200-day averages

Short interest at 3.7% of shares outstanding